 Introduction  Classification of inotropes  Postoperative myocardial dysfunction.  Choice of inotrope  Indications in specific settings.

Slides:



Advertisements
Similar presentations
Ionotropic Therapy in Acute Heart Failure
Advertisements

Lecture:10 Contractility, Stroke volume and Heart Failure
Dr Bronwyn Avard, July 2010  To understand the basic physiology of shock  To understand the pharmacodynamics and pharmacokinetics of vasoactive drugs.
 Cardiovascular System – Heart and Blood Vessels Topics in Human Pathophysiology Fall 2011 Gilead Drug Safety and Public Health.
A Look Into Congestive Heart Failure By Tim Gault.
Circulatory Adaptations to Exercise
 By the end of this lecture the students are expected to:  Define cardiac output, stroke volume, end- diastolic and end-systolic volumes.  Define physiological.
Congestive heart failure
Intra-aortic Balloon Pump (IABP)
© Continuing Medical Implementation …...bridging the care gap Valvular Heart Disease Aortic Stenosis.
Cardioanaesthesia. Coronary artery disease O 2 delivery Coronary blood flow = directly related to coronary perfusion pressure (CPP) CPP = aortic diastolic.
Cardiovascular system in its context Reverend Dr. David C.M. Taylor School of Medical Education
Pharmacology DOR 101 Abdelkader Ashour, Ph.D. 9 th Lecture.
Cardiogenic Shock and Hemodynamics. Outline Overview of shock – Hemodynamic Parameters – PA catheter, complications – Differentiating Types of Shock Cardiogenic.
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
ANESTHESIA FOR AORTIC SURGERY By: DR. Ahmed Mostafa Assist. Prof. of anesthesia Benha faculty of medicine.
Ischemic heart disease
Cardiac Output When the heart contracts Cardiac Vocabulary Contractility: Contractility is the intrinsic ability of cardiac muscle to develop force for.
2013 Cardiac output 1 Cardiac Output Prof. K. Sivapalan.
HEART FAILURE PROF. DR. MUHAMMAD AKBAR CHAUDHRY M.R.C.P.(U.K) F.R.C.P.(E) F.R.C.P.(LONDON) F.A.C.C. DESIGNED AT A.V. DEPTT F.J.M.C. BY RABIA KAZMI.
Cardiovascular management
Drugs for CCF Heart failure is the progressive inability of the heart to supply adequate blood flow to vital organs. It is classically accompanied by significant.
CONCEPTS OF NORMAL HEMODYNAMICS AND SHOCK
PHARMAKOLOGY VASOPRESSOR DRUGS DJUDJUK RAHMAD BASUKI Lab.Anestesi dan Terapi Intensive RSSA Malang.
Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
Vasoactive Drugs and Shock
Treatment of Heart Failure Claire Hunter, MD. Treatment of Heart Failure Goals Improve quality of life Prolong life Ejection fraction most important.
 By the end of this lecture the students are expected to:  Understand the concept of preload and afterload.  Determine factors affecting the end-diastolic.
Copyright ©2010 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. Understanding EKGs: A Practical Approach, Third Edition.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
OBJECTIVES At the end of lectures the students should Describe the different classes of drugs used for treatment of acute & chronic heart failure.
Drugs for Congestive Heart Failure
The Human Body in Health and
Vasopressors.
Heart failure Dr Rafat Mosalli. Objectives Definition Definition Pathophysiology Pathophysiology Age specific Causes Age specific Causes Clinical pictures.
Frank-Starling Mechanism
Nursing and heart failure
Cardiovascular Physiology { Function }
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
PICU Resident Talk Stanford School of Medicine Pediatric Critical Care Medicine June 2014.
Inferior/Right Ventricular Infarction CLINICAL PRESENTATION AND TREATMENT Lady Minto Hospital Emergency Rounds February 2015 Prepared by Shane Barclay.
3/24/04 Cardiac Inotropic Drugs. 3/24/04 Pathogenesis of congestive heart failure A number of compensatory mechanisms come into play during the development.
Cardiogenic Shock Dr. Belal Hijji, RN, PhD October 12 & 15, 2011.
Systolic Versus Diastolic Failure. Forms of Heart Failure Sytolic Failure Inability of the ventricle to contract normally and expel sufficient blood Inadequate.
Heart Prepared by Dr F.Nikbakht Assistant professor of Medical school.
 Heart disease remains the leading cause of morbidity and mortality in industrialized nations.  40% of all deaths in the U.S.A (nearly twice the number.
Overview of Receptors and Drugs
 By the end of this lecture the students are expected to:  Explain how cardiac contractility affect stroke volume.  Calculate CO using Fick’s principle.
By: Affan Malik Physiology 1 Case Study. Cardiac output: The amount of blood being pumped by the heart, coming from the ventricles into the aorta per.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Congestive heart failure Dr/Rehab Gwada. Objectives – Define Congestive Heart Failure. – Outlines the Factors Affecting Cardiac Output – Discuses the.
Heart Failure  Dfinition:  Clinical features  Underlying causes of HF include Arteriosclerotic heart disease, MI, hypertensive heart disease, valvular.
N Engl J Med 2010;362: R3 CHAE JUNGMIN/ Prof KIM MYENGGON.
Volume administration Overload Hypovolemia. Volume and the failing RV Volume overload Increased wall tension Reduced contractility.
1 Topics to be addressed: Blood Anatomy of Blood Vessels Anatomy of the Heart The Conduction System The Cardiac Cycle Cardiodynamics Blood Flow and its.
Drugs Used to Treat Heart Failure
Drugs for Heart Failure
Treatment of Congestive Heart Failure
Congestive heart failure
Inotropes & Vasopressors
The pathophysiology of myocardial infarction-induced heart failure
Traditional parenteral antihypertensive treatment
Sympathomimetics Domina Petric, MD.
2 Cardiovascular Physiology: Function.
Prepared by Shane Barclay
Anti hypertensive Drugs
Drugs Acting on the Heart
Inferior/Right Ventricular Infarction
Chapter 17: Function of the Heart
Recent advances – levosimendan
Presentation transcript:

 Introduction  Classification of inotropes  Postoperative myocardial dysfunction.  Choice of inotrope  Indications in specific settings

 An inotrope is an agent, which increases or decreases the force or energy of muscular contractions.  Positive inotropic agent enhances myocardial contractility so; cardiac output, the amount of blood ejected by the heart with each beat, will also increase. Introduction

 Maintenance of adequate oxygen balance is one of the primary objectives when dealing with patients undergoing cardiac surgery.  Cardiac output is one of the major components of oxygen delivery. Introduction (cont.)

Due to preoperative cardiac lesion and myocardial dysfunction secondary to the events related to cardiac surgery and cardio pulmonary bypass, circulatory support by pharmacological means is frequently required after surgery. Introduction (cont.)

Adrenergic receptors α- receptors α1α1 α2α2β-receptorsβ1β1β2β2 Introduction(cont.)

Classification of inotropic agents cAMP dependent agents adrenergic agonists dopaminergic agonists: phosphodiesterase III isoenzyme inhibitors: cAMP independent inotropic agents Na+-K+-ATPase inhibitors : Potassium channels inhibitors Agonists of β- adrenergic receptors Calcium Phenylephrine Other new agents Calcium Sensitizers vasopressin natriuretic brain peptide

 principal neurotransmitters in the sympathetic nervous system  potent α - adrenoceptor agonist strong vasoconstrictor  norepinephrine stimulates β 1-adrenoceptors, increases both heart rate and contractility.  Norepinephrine does not affect β 2- adrenoceptors.  Dose : 2-20µg/min( µg/kg/min )

 Hormone secreted by the adrenal medulla  Potent α - and β -adrenoceptor agonist.  so a powerful vasoconstrictor, a positive inotrope, and a positive chronotrope.  But, diastolic blood pressure may decrease as a result of vasodilation due to stimulation of β 2- adrenoceptor effects.  Dose : 2-20µg/min( µg/kg/min )

 An endogenous catecholamine  Stimulates both adrenergic and dopaminergic (D1 and D2) receptors.  Low-dose infusion (<5 µg/kg/min)  Intermediate doses (5-10 µg/kg/min).  Higher doses (>10 µg/kg/min)

 β 1-adrenergic agonist  Had positive inotropic and peripheral vasodilative properties.  As established dobutamine as a first line therapeutic choice in patients with decompensated HF.  Dose : µg/kg/min

 Inodilators  postreceptor” mechanism of action  oral administration.  Milrinone.  Dose : 50 µg/kg over 10 min, then µg/kg/min,max.: 1.13 mg/kg/min.

 It is one of calcium senstizers  It act by increasing the sensitivity of contractile apparatus (especially troponine-T) to intracellular calcium.  Proarrhythmic activity less common.  Induce peripheral, pulmonary and coronary vasodilatation, via ATP-sensitive potassium channels  Dose : is 6 to 12 µg/kg loading dose over 10 minutes followed by 0.05 to 0.2 µg/kg/min as a continuous infusion.

Causes:  aortic cross-clamping  inadequate myocardial protection  hypothermia with cardioplegia and topical iced solutions  surgical trauma  activation of the complement cascade by CPB  reperfusion injury  premature or excessive titration of inotropic agents

Recovery pattern of cardiac function: postoperative changes in the systolic myocardial performance after heart surgery in patients undergoing cardiopulmonary bypass (CPB)

Guided  The expected need for inotropes  clinical evidence of depressed myocardial function  Empirical drug choice and titration, with careful hemodynamic monitoring

Table 2. Predictive factors of inotropic support, as highlighted by several studies. Low ejection fraction (< 45%) History of congestive heart failure Cardiomegaly High LVEDP following ventriculogram MI within 30 days of operation* Older age (> 70 years) Longer duration of aortic cross-clamping Prolonged cardiopulmonary bypass* Urgent operation Re-operation* Female gender* Diabetes mellitus LVEDP = left ventricular end-diastolic pressure; MI = myocardial infarction. * statistical significance for coronary artery bypass surgery only.

Choice of inotropes(cont.)

 Catecholamines are the mainstay of current inotropic treatment  they can be divided into  more potent (epinephrine, isoproterenol, noradrenaline) and  milder (dopamine, dopexamine, dobutamine Choice of inotropes(cont.)

Dopamine Dobutamine EpinephrineNorepinephrine PDE inhibitors Levosimendan

 Coronary artery bypass graft surgery:  In most cases, no or only mild inotrope requirement.  inotropes may be needed in case of preexisting ventricular dysfunction or in case of unsuccessful revascularization if the intra-aortic balloon pump alone is not enough.

 emergency revascularization of acute myocardial infarction, dobutamine and PDE inhibitors.  off-pump coronary artery bypass graft surgery (dopamine, dobutamine) Indications in specific settings(cont.)

 Chronic heart failure : Combination therapy (i.e. a PDE inhibitor administered along with a beta-adrenergic inotrope, dobutamine or epinephrine) may therefore be the treatment of choice in these patients Indications in specific settings(cont.)

 Diastolic dysfunction : No inotropes at all (or inotropes with a better effect on ventricular relaxation, such as PDE inhibitors, if systolic dysfunction coexists) Indications in specific settings(cont.)

 valvular surgery Moderately severe aortic stenosis, Inotropic support is rarely needed Indications in specific settings(cont.)

Chronic aortic insufficiency Requiring adequate preload and inotropes Indications in specific settings(cont.)

Mitral stenosis, chronic mitral regurgitation Treatment with inotropes is warranted. Indications in specific settings(cont.)

Acute aortic and mitral regurgitation require aggressive inotropic support even preoperatively Indications in specific settings(cont.)

Tricuspid regurgitation Inotropes are beneficial Indications in specific settings(cont.)

 Orthotopic cardiac transplantation: Routine inotropic support includes isoproterenol (to increase the automaticity, inotropism and pulmonary vasodilation) and dopamine (to add further support whilst maintaining the systemic perfusion pressures). Indications in specific settings(cont.)

 Right ventricular dysfunction:  heart transplantation,  lung transplantation  pulmonary thromboendoarterectomy  left ventricular assist device implantation,  inadequate myocardial protection Indications in specific settings(cont.)

Successful management Right ventricular afterload The contractile strength maintenance of the aortic blood pressure pulmonary vasodilators inotropes : dobutamine, isoproterenol, epinephrine, PDE inhibitors vasoconstrictors

Conclusion

 Postoperative myocardial dysfunction is a major concern in the setting of cardiac surgery since it is extremely frequent and is related to a greater morbidity and mortality.  Inotropic drugs are nowadays an important therapeutic tools in the treatment of perioperative heart failure.  Good selection usually guide our outcome.